Assessment of EGFR Mutation Status in Matched Plasma and Tumor Tissue of NSCLC Patients from a Phase I Study of Rociletinib (CO-1686). (Q46093703)
Jump to navigation
Jump to search
scientific article published on 8 January 2016
Language | Label | Description | Also known as |
---|---|---|---|
English | Assessment of EGFR Mutation Status in Matched Plasma and Tumor Tissue of NSCLC Patients from a Phase I Study of Rociletinib (CO-1686). |
scientific article published on 8 January 2016 |
Statements
Assessment of EGFR Mutation Status in Matched Plasma and Tumor Tissue of NSCLC Patients from a Phase I Study of Rociletinib (CO-1686) (English)
Chris Karlovich
Jonathan W Goldman
Jong-Mu Sun
Elaina Mann
Krzysztof Konopa
Wei Wen
Philipp Angenendt
Leora Horn
David Spigel
Benjamin Solomon
D Ross Camidge
Shirish Gadgeel
Cloud Paweletz
Lin Wu
Sean Chien
Patrick O'Donnell
Shannon Matheny
Darrin Despain
Lindsey Rolfe
Mitch Raponi
Andrew R Allen
Keunchil Park
Heather Wakelee
Jean-Charles Soria
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference